ArticleJournal of nanobiotechnology2025
Low-intensity pulsed ultrasound (LIPUS)-augmented calcicoptosis by calcium-based nanoparticles for enhanced immunogenic cell death induction in triple-negative breast cancer.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Calcium dysregulation in breast cancer progression: mechanisms of calcicoptosis and therapeutic implications.Cancer gene therapy · 2026Review
- Metal-dependent regulated cell death: Molecular architecture and translational frontiers.iMeta · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) shows limited therapeutic efficacy due to the absence of effective targeted treatment options, with its immunosuppressive tumor microenvironment further diminishing the effectiveness of immunotherapy. Intracellular Ca²⁺ homeostasis plays a critical role in cancer progression, yet the efficacy of traditional inorganic nanoparticles in inducing calcicoptosis through Ca²⁺ release is constrained by poor water solubility, stability, and delivery efficiency. To address these challenges, we developed novel nanoparticles (NPs) by coordinating Ca²⁺ with the natural bioactive compound glycyrrhizic acid to create a multifunctional carrier (GC NPs), which was further loaded with the therapeutic natural compound curcumin (CUR) to form GC@CUR NPs. Through synergistic effects of Ca²⁺ overload and CUR-mediated regulation, these NPs significantly promote Ca²⁺ accumulation in mitochondria, triggering mitochondrial dysfunction and efficiently inducing calcicoptosis. Additionally, low-intensity pulsed ultrasound (LIPUS)-mediated targeted release markedly improved antitumor effects. Importantly, this strategy effectively induces immunogenic cell death (ICD) in TNBC, thereby significantly boosting antitumor immune responses. This study provides an innovative and efficient strategy for integrating chemotherapy and immunotherapy to transform TNBC tumors into immunoresponsive ones, offering new possibilities for comprehensive TNBC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.